Company profile

Ipsen specializes in the research, development, manufacturing and marketing of medications. Sales break down by family of products as follows:
  • specialty drugs (89.3%). Sales break down by therapeutic area between oncology (80.2%), neuroscience (17%) and rare diseases (2.8%);
  • consumer healthcare products (10.7%): products used in the treatment of gastrointestinal disorders, neurodegenerative pathologies and rheumatological disorders.
At the end of 2019, the group had 8 research and development centres located in France (2), the United Kingdom (2), the United States, Germany, Ireland and China, and 8 production sites worldwide. Sales are distributed geographically as follows: France (12.5%), Germany (7.3%), Italy (4.5%), Spain (4.1%), the United Kingdom (4.1%), Europe (19.4%), North America (30.1%), Asia (8.9%) and other (9.1%).

Source: Cofisem - Last Update: 19 Feb 2020
Key Executives
CEO Ad Interim Aymeric Le Chatelier
Chief Financial Officer Aymeric Le Chatelier
VP, Communication Christian Marcoux
Investor Relations Director Myriam Koutchinsky
General Counsel Francois Garnier
Director Research & Development Howard Mayer
Human Resources Director Regis Mulot
Source: Cofisem - Last Update: 02 Jan 2020
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales 2,576,200 2,224,800 1,908,700 1,584,600 1,443,900
Income from ordinary activities 2,692,800 2,348,400 2,011,700 1,671,100 1,520,200
Operating income -33,400 519,400 397,200 304,600 244,000
Cost (net) of financial indebtedness -28,000 -5,300 -8,100 -4,900 -2,900
Equity-accounted companies' contribution to results 3,700 1,100 1,400 1,900 2,500
Net profit from discontinued activities 4,300 2,100 2,200 100 600
Net income -50,200 389,100 272,900 226,500 190,800
Net income (Group share) -50,700 389,500 272,300 225,900 189,900
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 19 Feb 2020
Shareholder information
Mayroy 56.40 %
Free float 41.32 %
Group-owned stock 0.89 %
Source: Cofisem - Last Update: 05 Apr 2019

Address

Ipsen

65 Quai Georges Gorse
FR-92100 Boulogne-Billancourt
France
Source: Cofisem - Last Update: 19 Feb 2020

Contact

David Schilansky
Phone number: +33 1 44 30 43 88
Source: Ipsen - Last Update: 19 Feb 2020